SCHEMBL719030

SCHEMBL719030

COc1ccc2oc(C(O)C3CCCCC3)c(Br)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 7/20 0.41
ALDH1A1 P00352 6/20 0.41
HPGD P15428 6/20 0.41
HSD17B10 Q99714 4/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 4/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ESR1 P03372 1/20 0.38
NR4A1 P22736 1/20 0.38
APEX1 P27695 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718063 0.86 RAB9A (0.57) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL718966 0.85 RAB9A (0.45) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL721051 0.77 NPC1 (0.45) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL719390 0.77 NPC1 (0.45) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL717242 0.74 KDM4E (0.50) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL718939 0.74 RAB9A (0.54) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL718490 0.74 NPC1 (0.46) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL720875 0.73 RAB9A (0.46) RAB9ANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL719244 0.73 NPC1 (0.44) RAB9ANPC1KDM4EALDH1A1HSD17B10
SCHEMBL716374 0.73 RAB9A (0.65) RAB9ANPC1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885KDM4E 1907/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885KDM4E 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.